# Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment

> **NCT07711171** · PHASE4 · RECRUITING · sponsor: **Fudan University** · enrollment: 60 (estimated)

## Conditions studied

- Type 2 Diabetes Mellitus
- Cognitive Impairment

## Interventions

- **DRUG:** Canagliflozin group
- **DRUG:** Sitagliptin
- **DRUG:** Acarbose

## Key facts

- **NCT ID:** NCT07711171
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-19
- **Primary completion:** 2026-10-30
- **Final completion:** 2026-10-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07711171

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07711171, "Efficacy and Safety of Canagliflozin in the Treatment of Type 2 Diabetes With Mild Cognitive Impairment". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07711171. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*